AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36155369
Drug: Tramadol injections
RxNorm normalized name: tramadol Injectable Solution
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol injections (100 mg every 8 hours)
Trial: 35975404
Drug: Vibegron 75
RxNorm normalized name: vibegron 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibegron 75 mg once daily for 12 weeks
Trial: 32321085
Drug: Mindfulness-integrated cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-integrated cognitive behavior therapy (MICBT)
Trial: 34011049
Drug: Warming needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming needle moxibustion treatment for ankylosing spondylitis for 30 days followed by a 6-month follow-up.
Trial: 33211166
Drug: Cardiac index
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac index > 2.5 L/min/m2
Trial: 35212235
Drug: Intranasal esketamine
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intranasal esketamine 84 mg
Trial: 34246251
Drug: Non-opioid prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-opioid prescription
Trial: 32407242
Drug: Oral ketone
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketone ester (KE) intake (60 g carbohydrates/h combined with three boluses of 25, 20, and 20 g (R)-3-hydroxybutyl (R)-3-hydroxybutyrate)
Trial: 33305513
Drug: sacubitril/valsartan (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sacubitril/valsartan (target dose 97/103 mg twice daily)
Trial: 33305513
Drug: valsartan (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan (target dose 160 mg twice daily)
Trial: 32779826
Drug: Over-the-phone supportive
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over-the-phone supportive care tailored to the needs of oral cancer patients, provided by a health professional
Trial: 34186135
Drug: Annual prostate-specific
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual prostate-specific antigen (PSA) tests for 6 years and digital rectal exams (DRE) for 4 years
Trial: 35487546
Drug: Discreet pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discreet pill containers
Trial: 32330670
Drug: TACTICS implementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACTICS implementation (context-tailored implementation approach) after provider training in prolonged exposure therapy (PE) for PTSD.
Trial: 32330670
Drug: Provider training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provider training in prolonged exposure therapy (PE) alone.
Trial: 32041661
Drug: Prepectoral implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepectoral implant placement
Trial: 32041661
Drug: Subpectoral implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subpectoral implant placement
Trial: 36263035
Drug: Slow-paced breathing
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-paced breathing (4sec inhalation, 6sec exhalation for 20 minutes 3x daily)
Trial: 36263035
Drug: Slow-paced breathing
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-paced breathing (dose-response relationship)
Trial: 32131866
Drug: IC43 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC43 100 μg
Trial: 39499492
Drug: pembrolizumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab + chemotherapy
Trial: 35855386
Drug: Citrus aurantium
RxNorm normalized name: Citrus aurantium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrus aurantium essential oil (5 drops, twice a day for one month)
Trial: 35855386
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice a day for one month)
Trial: 33954198
Drug: PECS II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PECS II (0.5% ropivacaine 25 ml)
Trial: 35616436
Drug: Naltrexone and
RxNorm normalized name: Naltrexone and Bupropion Hydrochlorides Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone and acamprosate (alone and in combination)
Trial: 32785710
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) 0.5 mg/kg intravenously twice daily for 5 days
Trial: 32188386
Drug: Established markers
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Established markers of inflammation (e.g., C-reactive protein)
Trial: 32188386
Drug: Newer inflammatory
RxNorm normalized name: Arthriten Inflammatory Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer inflammatory markers (e.g., lipoprotein-associated phospholipase A2, cytokines, myeloperoxidase)
Trial: 32188386
Drug: Anti-inflammatory and
RxNorm normalized name: MENTHOL 20 mg in 1 mL TOPICAL CREAM [Phoenix KinetiCream Anti-inflammatory and Pain Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory and pleiotropic drugs
Trial: 32438719
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of grapefruit, bitter orange, and olive extracts for eight weeks
Trial: 35894768
Drug: Routine hypoglycemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine hypoglycemic drugs + resistance training (AE + RT)
Trial: 35894768
Drug: Routine hypoglycemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine hypoglycemic drugs
Trial: 33499570
Drug: Pulsed Dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Dye Laser (PDL) treatment every 1 week
Trial: 33499570
Drug: Pulsed Dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Dye Laser (PDL) treatment every 2 weeks
Trial: 33499570
Drug: Pulsed Dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Dye Laser (PDL) treatment every 3 weeks
Trial: 33499570
Drug: Pulsed Dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Dye Laser (PDL) treatment every 4 weeks
Trial: 34284099
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment in poor CYP2D6 metabolizers
Trial: 34284099
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment in intermediate CYP2D6 metabolizers
Trial: 34284099
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment in normal CYP2D6 metabolizers
Trial: 34284099
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment in ultrarapid CYP2D6 metabolizers
Trial: 35162842
Drug: Submucosal intralesional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submucosal intralesional injections of dexamethasone (2 mL; 4 gm/mL)
Trial: 34541864
Drug: TARE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TARE plus chemotherapy
Trial: 34924512
Drug: Cognitive-Behavioral-Based Physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral-Based Physical Therapy (CBPT-Trauma)
Trial: 32631130
Drug: Mobile interventionist
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile interventionist approach as an add-on to assertive community treatment (ACT)
Trial: 32631130
Drug: Assertive community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertive community treatment (ACT) alone
Trial: 33965364
Drug: Online weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online weight management platform with weekly coaching calls (weeks 1–12) tapered to bi-weekly calls (weeks 12–24)
Trial: 32907547
Drug: BELIEF protocol
RxNorm normalized name: Ora Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BELIEF protocol (two face-to-face counseling sessions at 24 and 34 weeks of pregnancy, plus eight weekly telephone counseling sessions)
Trial: 33981369
Drug: Probiotic supplement
RxNorm normalized name: Align Probiotic Supplement Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplement preparation (PSP)
Trial: 36152764
Drug: 25% IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% IV albumin 1.5 g/kg weekly infusions
Trial: 34484562
Drug: Anthocyanin-rich mulberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthocyanin-rich mulberry milk (2 servings daily)
Trial: 34484562
Drug: Anthocyanin-rich mulberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthocyanin-rich mulberry milk (1 serving daily)
Trial: 32673160
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise training at 65-85% V̇o2peak for 24 weeks, prescribed dose of 8 kcal·kg body wt‐1·wk‐1 (8 KKW) or 20 KKW
Trial: 37001859
Drug: Cemiplimab plus
RxNorm normalized name: cemiplimab
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab plus chemotherapy (350 mg every 3 weeks for up to 108 weeks)
Trial: 38820979
Drug: Cemiplimab plus
RxNorm normalized name: cemiplimab
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab plus chemotherapy
Trial: 33550716
Drug: Cold atmospheric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold atmospheric plasma (CAP) pretreatment before topical anesthetic cream application
Trial: 33550716
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic cream only (control)
Trial: 33389549
Drug: Clazosentan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazosentan (20 mg/h followed by 60 mg/h continuous infusion)
Trial: 33389549
Drug: Clazosentan (simulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazosentan (simulated 15 mg/h for 3 hours)
Trial: 33149899
Drug: Various therapeutic
RxNorm normalized name: Various therapeutic radiopharmaceuticals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various therapeutic agents tested in adaptive platform trials
Trial: 33259247
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training (CT) (n=14)
Trial: 35255929
Drug: Mesenchymal stromal
RxNorm normalized name: Mesenchymal Stromal Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stromal cells (MSCs) plus basiliximab and calcineurin inhibitor
Trial: 33899447
Drug: Complex spa
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex spa treatment with transcranial magnetic therapy (TCMT)
Trial: 33899447
Drug: Identical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical treatment complex without TCMT (Control)
Trial: 33899447
Drug: Complex spa
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex spa treatment with TCMT
Trial: 34033812
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg daily until delivery
Trial: 33321501
Drug: Guided internet-
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet- and mobile-based intervention (IMI) tailored to CBP plus treatment-as-usual (TAU)
Trial: 33136049
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received only standard IANB injection of 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Trial: 32295442
Drug: Integrative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative treatment (Western medicine combined with Jianpi Huatan Tongfu granule)
Trial: 32295442
Drug: Western medical
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medical treatment
Trial: 34018381
Drug: Inhalation aromatherapy
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation aromatherapy with Rosa damascena (5 drops of 40% for 20 minutes)
Trial: 34018381
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (inhalation of distilled water)
Trial: 34018381
Drug: Inhalation aromatherapy
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation aromatherapy with Rosa damascena
Trial: 35358592
Drug: Bevacizumab (subconjunctival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (subconjunctival 2.5 mg/0.1 ml at surgery and topical 10 mg/ml 4 times per day for 4 weeks)
Trial: 34229619
Drug: Telephone therapist
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone therapist delivered cognitive behavioural therapy (TCBT)
Trial: 34229619
Drug: Web-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based cognitive behavioural therapy (WCBT)
Trial: 32166564
Drug: T3-L-CGMs (50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T3-L-CGMs (50% level of T1)
Trial: 34453878
Drug: Group-based treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based treatments
Trial: 32092060
Drug: ALVAC-HIV (vCP2438)
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
Trial: 32298501
Drug: 100% insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% insulin dose
Trial: 32298501
Drug: 130% insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 130% insulin dose
Trial: 32298501
Drug: 145% insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 145% insulin dose
Trial: 32298501
Drug: 160% insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160% insulin dose
Trial: 33575961
Drug: Thymus thymalin
RxNorm normalized name: THYMUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymus thymalin (peptide drug)
Trial: 34085478
Drug: Penetrating moxibustion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penetrating moxibustion at governor vessel, 2 h per treatment, once a week for 4 weeks
Trial: 34085478
Drug: Momethasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Momethasone furoate nasal spray, 2 sprays per side per time, once a day for 4 weeks
Trial: 32141112
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) - 12 sessions of 20 minutes each, energy/session 4.08 J/cm2, thrice/week
Trial: 32141112
Drug: Non-contact selective-field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-contact selective-field radiofrequency (NcRF) - four 30-minute treatments once/week
Trial: 34210681
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg Q3W plus ipilimumab 50 mg Q6W for 4 doses (PEM200+IPI50)
Trial: 34210681
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg Q3W plus ipilimumab 100 mg Q12W for 4 doses (PEM200+IPI100)
Trial: 35129010
Drug: Gluteal trigger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluteal trigger point injection (TP)
Trial: 35415804
Drug: Enhanced arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced arm (didactic plus weekly messaging and monetary inducement)
Trial: 34934054
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg kg-1) acute
Trial: 33524917
Drug: Radically open
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radically open dialectical behavior therapy (RO DBT)
Trial: 39028879
Drug: Dual antithrombotic
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antithrombotic therapy (DAT)
Trial: 35137493
Drug: Intranasal naloxone
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal naloxone (1.4 mg/0.1 mL)
Trial: 35137493
Drug: Intramuscular naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular naloxone (0.8 mg/2 mL)
Trial: 33257495
Drug: Concurrent Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Treatment of PTSD and Substance Use Using Prolonged Exposure - Adolescent (COPE-A)
Trial: 35123427
Drug: Next pharmacological
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Next pharmacological step (switch to tricyclic antidepressant or augmentation with lithium or second-generation antipsychotic) combined with CBT
Trial: 32481305
Drug: Shenfu Qiangxin
RxNorm normalized name: Dianexin
DrugBank: Dianexin (DB15000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu Qiangxin Pills (SFQX)
Trial: 35546412
Drug: Customized app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Customized app with individual feedback regarding self-reported medication intake for 12 months
Trial: 35546412
Drug: Customized app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Customized app without individual feedback regarding self-reported medication intake for 12 months
Trial: 33026243
Drug: Ertugliflozin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin (5 mg, 15 mg pooled)
Trial: 32577113
Drug: Automated daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated daily text-messages regarding pain, opioid utilization, and a daily CBT intervention
Trial: 35718313
Drug: Healthy comfort
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy comfort food (e.g., grapes)
Trial: 35718313
Drug: Unhealthy comfort
RxNorm normalized name: Comfort Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unhealthy comfort food (e.g., chips)
Trial: 33276744
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (45 min once a week for 12 weeks)
Trial: 34035312
Drug: Fluticasone furoate/umeclidinium/vilanterol
RxNorm normalized name: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 mcg via ELLIPTA
Trial: 34035312
Drug: Tiotropium (TIO)
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (TIO) 18 mcg via HandiHaler
Trial: 35124187
Drug: Investigators' practices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators' practices following trial discontinuation
Trial: 34060027
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NACT) followed by cold knife conization (CKC)
Trial: 35745176
Drug: Test potato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test potato cv. SQ containing 45 mg anthocyanin
Trial: 34116176
Drug: Ciprofol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofol 0.5 mg/kg
Trial: 34619937
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of community-based comprehensive intervention and internet-based intervention (Group B)
Trial: 34048716
Drug: 4 weeks
RxNorm normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of amoxicillin‐clavulanate (25‐35 mg/kg twice daily oral suspension)
Trial: 34048716
Drug: 2 weeks
RxNorm normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 weeks of amoxicillin‐clavulanate followed by 2 weeks of placebo
Trial: 34048716
Drug: 4 weeks
RxNorm normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of amoxicillin‐clavulanate
Trial: 35460434
Drug: 4 weeks’
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks’ daily remote ischaemic conditioning (CRIC)
Trial: 38184633
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (control group).
Trial: 36167307
Drug: G-CSF (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (starting at day +3 post Auto-HSCT)
Trial: 36167307
Drug: No G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No G-CSF (G-CSF withheld after Auto-HSCT)
Trial: 36167307
Drug: G-CSF and
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF and No G-CSF